What is the recommended dose of Lantus (insulin glargine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Dosing for Lantus (Insulin Glargine)

For patients with diabetes requiring insulin therapy, the recommended starting dose of Lantus (insulin glargine) is 0.2 units/kg or up to 10 units once daily for type 2 diabetes, and approximately one-third of the total daily insulin requirements for type 1 diabetes. 1

Initial Dosing Guidelines

Type 1 Diabetes

  • The recommended starting dose is approximately one-third of the total daily insulin requirements 1
  • Total daily insulin requirements typically range from 0.4 to 1.0 units/kg/day, with 0.5 units/kg/day being typical for metabolically stable patients 2, 3
  • Must be used with short-acting, premeal insulin to satisfy the remainder of daily insulin requirements 1
  • Higher doses may be required during puberty, menses, and medical illness 2

Type 2 Diabetes

  • The recommended starting dose is 0.2 units/kg or up to 10 units once daily 1
  • For insulin-naive patients, starting with 0.1-0.2 units/kg/day is appropriate 3
  • Most patients can be taught to uptitrate their own insulin dose by adding 1-2 units (or 5-10% for higher doses) once or twice weekly if fasting glucose levels remain above target 3

Dose Titration

  • Increase the dose by 2-4 units every 3-4 days until fasting blood glucose reaches target range (80-130 mg/dL) 3, 4
  • If fasting glucose is ≥180 mg/dL, consider increasing the dose by 4 units 3, 4
  • The American Diabetes Association recommends increasing the basal insulin dose by 10-15% or 2-4 units once or twice weekly until fasting blood glucose target is met 2

Administration Timing

  • Administer subcutaneously once daily at any time of day, but at the same time every day 1
  • Studies show that morning, dinner, or bedtime administration are all effective with similar glycemic control 5
  • Morning administration may result in fewer nocturnal hypoglycemic events compared to dinner or bedtime dosing 5, 6

Special Populations and Situations

  • For patients on enteral/parenteral feeding requiring insulin, a reasonable starting point is 10 units of insulin glargine every 24 hours 3
  • For patients with higher risk of hypoglycemia (elderly, renal impairment), consider using the lower end of the dosing range 3
  • For patients with retinopathy or eGFR <60 mL/min/1.73 m², a lower starting dose of approximately 0.12 units/kg/day may be appropriate 7

Common Pitfalls to Avoid

  • Delaying insulin therapy in patients not achieving glycemic goals can be harmful 3
  • Not adjusting doses based on self-monitoring of blood glucose levels can lead to poor glycemic control 3
  • Overbasalization (using higher than necessary basal insulin doses) can mask insufficient mealtime insulin coverage 3
  • Failure to recognize that insulin requirements may change with weight changes, illness, or changes in physical activity 3

Switching from Other Insulin Therapies

  • When switching from once-daily NPH insulin to once-daily Lantus, use the same dosage 1
  • When switching from twice-daily NPH insulin to once-daily Lantus, use 80% of the total NPH dosage 1
  • When switching from TOUJEO (insulin glargine 300 units/mL) to Lantus (100 units/mL), use 80% of the TOUJEO dosage 1

Lantus provides consistent, 24-hour basal insulin coverage with reduced risk of hypoglycemia compared to NPH insulin, particularly nocturnal hypoglycemia (26% reduction in nocturnal and 46% reduction in severe hypoglycemia) 8.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.